TrialThe oncologist2016

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Ning Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.